"The Efficacy and Safety of Aripiprazole and Paliperidone 1 and 3-Month Long-Acting Preparations During The Maintenance of Schizophrenia in Clinical Practice"

Gokce Saridogan[1], Neset Nesetoglu[2], Sema Ketenci[3], Nazife Acet[4], Duri Sehvar Unal[2], and Mehmet Zafer Goren[5]

[1]Istanbul Erenkoy Mental and Nervous Diseases Training and Research Hospital
[2]Istanbul University
[3]Atlas University
[4]Istanbul Medeniyet University
[5]Marmara University School of Medicine

January 24, 2023

Abstract

Aim: To our knowledge; this is the first study that compared the efficacy and safety of aripiprazole 1-month and paliperidone 1-month and paliperidone 3-month long-acting forms preparations as well as plasma drug levels during the maintenance treatment of schizophrenia in the real world. Method: In our study, subjects were evaluated every month for four months with relevant psychiatric measures and plasma drug levels. Follow-up days were determined as days 0, 30, 60, and 90. Plasma drug levels of the treatments were analyzed by using LC/MS-MS. Results: No superiority was observed between the groups regarding PANSS positive and general psychopathology ($p>0.05$). It was observed that PANSS negative and total scores were statistically lower in the aripiprazole once-monthly group than in the paliperidone 3-month preparations ($p<0.05$). We observed that Quality of Life Scale interpersonal relations scores, the aripiprazole 1-month group exhibited higher scores than both of the paliperidone groups. Aripiprazole 1-month group scored higher than the paliperidone 1-month group in the intrapsychic foundations subscale ($p<0.05$). No significant difference was observed between extrapyramidal adverse effect, akathisia, and insight levels among the three groups ($p>0.05$). Aripiprazole 1- month group scored significantly lower than both paliperidone groups in the Arizona Sexual Experiences Scale ($p<0.001$). Aripiprazole metabolite was negatively correlated with depressive symptoms in the Calgary Depression Assessment Scale in Schizophrenia ($p<0.05$) and the Barnes Akathisia Rating Scale ($p<0.05$). Conclusion: Aripiprazole once-monthly showed superiority in efficacy aspects to PP3M but not PP1M and similar safety with both paliperidone formulations.

The Efficacy and Safety of Aripiprazole and Paliperidone 1 and 3-Month Long-Acting Preparations During The Maintenance of Schizophrenia in Clinical Practice

Running head: Aripiprazole and Paliperidone Long-Acting Forms

Gökçe Elif Sarıdoğan[1,5], Neşet Neşetoğlu[2,6], Sema Ketenci[3], Nazife Gökçe Akpınar[4], Mehmet Zafer Gören[5], Durişehvar Özer Ünal [2,6]

1-Erenkoy Psychiatry Training and Research Hospital, Department of Psychiatry

2 Istanbul University, Faculty of Pharmacy, Department of Analytical Chemistry, Beyazıt/Istanbul

3- Atlas University Faculty of Medicine, Internal Medicine, Department of Medical Pharmacology

4- Family Health Center No. 5 Gebze

5- Marmara University Faculty of Medicine, Department of Medical Pharmacology

6- Istanbul University, Drug Research and Application Center, Beyazıt /İstanbul

Corresponding author:

Gokce Elif SARIDOGAN, MD

University of Health Sciences Istanbul Erenkoy Mental Health and Neurological Diseases Education and Research Hospital,

Sinan Ercan Cad. No:29, 34736 Kazasker, Erenkoy-Kadikoy/Istanbul/TURKEY.

GSM: +905325032797

drgokcesaridogan@gmail.com

The authors confirm that the Principal Investigator for this observational study is Gokce Elif Saridogan and that they had direct clinical responsibility for patients.

Ethical approval

The Clinical Ethics Committee of Marmara University Medical Faculty approved the study protocol (09.2019.468, date:03.05.2019). The data collection process was performed in accordance with the rules of the Declaration of Helsinki.

Declarations of Interest

None.

Funding

This research received grant from the Istanbul University (DRC2022-005)

Hosted file

`aripiprazolevspaliperidoneLAI-maintext.docx` available at https://authorea.com/users/579408/articles/620854--the-efficacy-and-safety-of-aripiprazole-and-paliperidone-1-and-3-month-long-acting-preparations-during-the-maintenance-of-schizophrenia-in-clinical-practice